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The monitoring of minimal residual disease (MRD) through low sensitivity real-time (RT) polymerase chain
reaction (PCR) analysis of BCR-ABL transcripts allows early detection of chronic myeloid leukemia (CML)
relapse after allogeneic hematopoietic stem cell transplantation (HSCT). The introduction of more sensitive
techniques, such as RT quantitative (Q)-PCR, may lead to an overestimation of the risk of CML relapse. In this
study, we reviewed the results of peripheral blood RT Q-PCR in CML patients who underwent allogeneic HSCT
from 1983 to 2007. In our laboratory, RT Q-PCR analysis was routinely performed since 2002. Eighty-seven of
189 patients had available RT Q-PCR data; 63 patients had at least 3 RT Q-PCR analyses assessable. Fifty-two of
63 patients (83%) had, at least once, detectable transcript levels, but with an BCR-ABL/ABL ratio <.1% deﬁned
as <MR3 (molecular remission <0,1%), whereas 11 (17%) had persistent undetectable BCR-ABL transcripts. Six
of 52 patients with <MR3 relapsed, deﬁned as BCR-ABL transcript numbers >.1% conﬁrmed by the ﬁnding of
Phþ cells in bone marrow. No patients with persistent undetectable transcripts relapsed (P ¼ .19). Relapse did
not correlate with the number of occurrences of <MR3 or with the time to the ﬁrst <MR3 result. Finally, of 46
patients with detectable transcripts who did not relapse, 35 had undetectable transcripts at last contact. RT Q-
PCR analysis had low speciﬁcity (19%) and low positive predictive value (12%) in predicting relapse of CML
patients after allogeneic HSCT. Our data suggest that detection of low BCR-ABL transcript levels by RT Q-PCR
analysis has a poor accuracy in deﬁning the risk of CML relapse and should not be considered as the unique
indication to treatment. Fluctuation of BCR-ABL transcripts levels is common as late as 10 years post-
transplantation, possibly suggesting the long-term persistence of CML stem cells.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION was similar to conventional metaphase cytogenetics
Allogeneic hematopoietic stem cell transplantation
(HSCT) has been used to treat patients with chronic myeloid
leukemia (CML) in the chronic phase for over 30 years. The
incidence of clinical relapse has been low, but some patients
have relapsed more than 10 years after an otherwise
“successful” transplantation [1]. Indeed, data collected by the
Center for International Blood and Marrow Transplant
Research show that the cumulative incidence of relapse at 15
years for patients in remission at 5 years posttransplantation
has been as high as 17% [2]. Thus, the issue of whether
patients transplanted for CML continue to harbor in their
body small quantities of residual leukemia after allogeneic
HSCT is still open.
We and others have previously observed that the detec-
tion of residual disease by polymerase chain reaction (PCR)
analysis correlates with relapse after bone marrow trans-
plantation [3]. The methodology used for detecting BCR-ABL
transcripts by PCR analysis has evolved over the years.
Previous low sensitivity PCR techniques, such as qualitative
single-step [4] or older quantitative competitive PCR
techniques [5], could predict the risk of relapse post-
transplantation [6,7]. However, the sensitivity of these assaysdgments on page 739.
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13.01.007(approximately 102). After 2000, the Taqman methodology
increased the sensitivity to 104 or more. Moreover, in 2003
a Europe Against Cancer program established standardized
protocols for BCR-ABL quantitation in multiple centers using
this methodology. Taqman-based real-time (RT) quantitative
(Q)-PCR is currently used in the follow-up of patients treated
with tyrosine kinase inhibitors (TKIs) and has improved
treatment strategies [8]; notably, RT Q-PCR may be positive
in many patients in complete cytogenetic remission.
However, the predictive value of RT Q-PCR analysis on the
risk of relapse after allogeneic HSCT is still debated [9]. This is
particularly important as treatment of early (molecular or
cytogenetic) relapses after allogeneic HSCTwith either donor
lymphocytes infusion [9-11] or TKIs has been shown to be
more effective than late (advanced) relapses and to induce
durable molecular responses [12-14]. In this article, we
review the results of RT Q-PCR analysis of BCR-ABL tran-
scripts in all patients with CML who underwent allogeneic
HSCT at our institute, between 1983 and 2007, and correlate
these results with the risk of relapse.
METHODS
Patients
We studied 189 consecutive patients with Philadelphia chromosome
(Ph) and BCR-ABLepositive CMLwho underwent allogeneic HSCT from 1983
through 2007 at the Department of Hematology and Oncology Sciences
“Seragnoli,” University of Bologna. Follow-up was updated as of January
2010. Because in our laboratory RT Q-PCR was routinely performed since
2002, only 87 patients had at least 1 BCR-ABL transcript quantitation
available. Of 87 patients, only 63 had at least 3 separate assessable RT Q-PCRTransplantation.
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whereas 13 had only 1 measurement. Only 2 more events could be observed
if the analysis was extended to these 24 patients (2 relapses, 1 in the
subgroup with 2 and 1 in the subgroup with only 1 measurement). Addi-
tional analyses were performed, including patients with 2 measurements,
and the results (not shown) were similar to those reported in the current
study. Therefore, the ﬁnal analysis included only 63 patients with 3 available
measurements. Fifteen patients were monitored with RT Q-PCR analysis
from the date of transplantation; for the remaining 48 patients, the median
time between the date of transplantation and the ﬁrst RT Q-PCR analysis
was 2607 days (range, 729 to 5321). The median number of Q-PCR
measurements per patients was 6; 14 patients had 10 quantiﬁcations.
The characteristics of the study group are summarized in Table 1. The
study group comprised 44 males and 19 females with a median age of
36 years (range, 13 to 56). At the time of transplantation, 68% patients were
in chronic phase and 32% in accelerated phase. Accelerated phase was
deﬁned based on standard European group of Blood and Marrow Trans-
plantion criteria by any of the following: anemia (hemoglobin <8 g/dL),
leukocytosis (white blood cell count > 100  109/L), thrombocytopenia
(platelets < 100  109/L), thrombocytosis (platelets > 1000  109/L), or
splenomegaly unresponsive to BU busulfan or hydroxyurea; extra-
medullary disease; clonal marrow cytogenetic abnormality(ies) in addition
to the original Ph chromosome; blood or marrow blasts>10%; and blood or
marrow blasts plus promyelocytes >20% and/or blood basophilsþ
eosinophils >20% [15]. Sixty-four percent of patients had been previously
treated with interferon-a and 22% with TKIs. All patients received a mye-
loablative conditioning regimen (67% busulfan based and 33% total body
irradiation based). Sixty percent of patients received low-dose antithy-
mocyte globulin (ATG; Fresenius, Bad Homburg, Germany) in the condi-
tioning regimen, as previously described [16]; 38% received the
transplantation from a unrelated donor; and 38% received peripheral blood
stem cells. All patients received cyclosporine and methotrexate as graft-
versus-host disease (GVHD) prophylaxis. We classiﬁed acute and chronic
GVHD according to standard criteria [17,18].Molecular Monitoring of Minimal Residual Disease
BCR-ABL transcript level assessment was performed using RT Q-PCR
according to suggested procedures and recommendations, as previously
described [19]. The cycle threshold was deﬁned as the cycle associated with
a signiﬁcant increase in ﬂuorescence and was correlated with the amount of
mRNA by using increasing amounts of plasmid RNA containing the mRNA of
interest, leading to the deﬁnition of a standard curve. Samples yielding an
ABL threshold cycle >30, corresponding to <1000 ABL transcript copies,
were considered as having degraded RNA and discarded. BCR-ABL transcriptTable 1
Patient Characteristics (N ¼ 63)
Age, yr (range) 36 (20-56)
Gender
Male 44 (69.8%)
Female 19 (30.2%)
Female-to-male 16 (25.4%)
Donor
Related 39 (61.9%)
Unrelated 24 (38.1%)
Source
BM 39 (61.9%)
PBSC 24 (38.1%)
Conditioning
Busulfan-based 42 (66.7%)
TBI-based 21 (33.3%)
ATG-containing 38 (60.3%)
Disease phase
Chronic phase 43 (68.3%)
Accelerated phase 20 (31.8%)
Previous treatments
Interferon-a 40 (63.5%)
Imatinib 14 (22.2%)
Acute GVHD
Grade I 11 (17.5%)
Grades II-IV 12 (19.1%)
Chronic GVHD
Limited 21 (33.3%)
Extensive 18 (28.6%)
BM indicates bone marrow; PBSC, peripheral blood stem cells; TBI, total
body irradiation.levels were expressed as a percentage of the amount of BCR-ABL/ABL ratio
according to the International Scale, taking advantage of the ongoing
international initiatives that standardize the quantitation of BCR-ABL tran-
scripts through the use of a conversion factor [20]. The lower detection limit
of the assay is 104. The reference laboratory that performed all molecular
analysis on this study was located in Bologna (conversion factor, .6), and the
data were checked and validated (10 samples at 3, 6, 9, and 12 months) in
Turin and Naples.
Monitoring of molecular disease (minimal residual disease [MRD]) was
planned to be performed every 3 months until 2 years, then every 6 months
until 5 years, and then yearly afterward. The ﬁrst analysis was performed at
3months posttransplantation. Only peripheral blood samples were included
in the analysis [21]. When detectable BCR-ABL occurred, monitoring was
performedmore frequently, as clinically indicated. Patients were included in
the low-level (<MR3 [molecular remission <0,1%]) detectable transcript
group when the BCR-ABL/ABL ratio was <.1%, according to the International
Scale in at least 1 sample during the follow-up [4]. All patients with
detectable transcript but with BCR-ABL/ABL ratio <.1% were included in the
<MR3 group. A single <MR3 result was sufﬁcient to include a patient in the
<MR3 group. Two or more consecutive results of <MR3 were grouped
together for purposes of analysis as “occurrences” (Table 2). Patients with
stable undetectable BCR-ABL were included in the undetectable BCR-ABL
group. Patients with conﬁrmed loss of the molecular response (BCR-ABL/
ABL ratio >.1% International Scale) and evidence of Phþ cells in bone
marrow upon cytogenetic analysis underwent preemptive treatment in
accordance with our local policy.
Statistical Analysis
Categorical variables were compared among groups by the chi-square
test. Continuous numeric variables were expressed as medians and
compared among groups by the Wilcoxon test. Statistical signiﬁcance was
set at .05. Multiple logistic regression analysis was used to identify the
independent prognostic factors for the outcomes. Variables with a P < .1
were included in the multivariate model. Curves representing the time to
clinical relapse were drawn according to the Kaplan-Meier method starting
from the time of the ﬁrst <MR3 result and compared by the log-rank test.
For patients with persistent undetectable BCR-ABL transcripts, the time to
relapse was calculated starting from the time of the ﬁrst Q-PCR analysis.
Sensitivity, speciﬁcity, and positive predictive and negative predictive values
were determined as follows:
Sensitivity : T=D 100
Specificity : ðall TÞ=ðall DÞ  100
Negative predictive value : all ðT and DÞ=ðall TÞ  100
Positive predictive value : T and D=T  100
where T is patients with an abnormal test result and D is patients with
disease.
Statistical analyses were performed by using Graph Pad Prism version
4.02 (GraphPad Software Inc. La Jolla, CA). Multivariate analyses were per-
formed using SPSS version 9.1 (IBM Italia, Segrate, MI).
RESULTS
Patients’ Molecular Status after Allogeneic
Transplantation
Of 63 patients, after a median follow-up of 3693 days
(range, 898 to 9405), 60 were still alive and 3 had died
without relapsing. Fifty-two patients had at least 1Table 2
Characteristics of Patients in the <MR3 Group (N ¼ 52)
Characteristics Value
Number of occurrences of <MR3 results*
1 29 (55.8)
2 17 (32.7)
3 6 (11.5)
Time to ﬁrst occurrence of a <MR3 resulty
<1 10 (19.2)
1-5 14 (26.9)
>5 28 (53.9)
* An occurrence is deﬁned as 1 consecutive positive results.
y Measured in years from transplantation.
M. Arpinati et al. / Biol Blood Marrow Transplant 19 (2013) 735e740 737occurrence of detectable low-level BCR-ABL transcripts
(<MR3) and were therefore included in the <MR3 group.
Eleven patients had persistent undetectable BCR-ABL tran-
scripts. As shown in Table 2, 29 patients had only 1 occur-
rence of a <MR3 result, as deﬁned in Methods; 17 patients
had 2 occurrences and 5 patients had 3 occurrences, whereas
1 patient had 4. Fifteen patients were monitored starting
from the date of transplantation: 10 patients had their
ﬁrst detectable BCR-ABL transcript within 1 year posttran-
splantation; in 7 of them, BCR-ABL transcripts were detect-
able at the ﬁrst analysis. In the remaining 37 patients, the
ﬁrst Q-PCR analysis was performed after a median of 1841
days (range, 729 to 5331) posttransplantation. In 28 patients,
the ﬁrst occurrence of a <MR3 result was observed at
5 years after transplantation, with only 9 of 28 patients
positive at their ﬁrst RT Q-PCR analysis. Among the other
9 patients, the ﬁrst occurrence of a <MR3 result was
observed at <5 years posttransplantation, with 6 patients
positive at their ﬁrst PCR analysis.
In univariate analysis, the occurrence of a <MR3 result
positively correlated with the administration of ATG during
conditioning and was more common in patients trans-
planted after 2002 (i.e., patients who were monitored with
RT Q-PCR starting at the time of transplantation) (Table 3). In
multivariate analysis, we observed a trend in which patients
who had received ATG pretransplantation (Table 3) were
more frequent in the <MR3 group. Other factors, including
the stage of the disease, the presence or absence of GVHD,
the type of donor, or the type of source, did not correlatewith
the results of BCR-ABL analysis posttransplantation (Table 3).
Impact of the Molecular Status on the Risk of Relapse
Six patients had relapsed at a median of 2142 days (range,
1419 to 3746) posttransplantation. At relapse, 2 patients were
in the blastic phase, 2 were in chronic phase, and 2 had only
cytogenetic evidence of the disease (UPN [Unique Patient
Number] 379 had 13%, whereas UPN 553 had 50% Phþ
metaphases in the bone marrow). The characteristics of
relapsed patients are described in Table 4.
When we analyzed the risk of relapse on the basis of RT
Q-PCR, we observed that 6 of 52 patients in the <MR3 group
relapsed after a median follow-up of 1094 days (range, 561 toTable 3
Risk of a <MR3 Result Posttransplantation (N ¼ 52)
Univariate Analysis Multivariate
Analysis
Female-to-male OR .32 (.08-1.26) P ¼ .19 n.p.
MUD OR 3.3 (.6-16.8) P ¼ .13 n.p.
PBSC OR 1.8 (.4-7.6) P ¼ .42 n.p.
ATG OR 5.5 (1.3-23) P ¼ .01 OR 3.5 (.8-15)
P ¼ .09
BMT after 2002 OR 9.5 (.5-172) P ¼ .04 Not signiﬁcant*
Previous interferon-a OR .13 (.01-1.1) P ¼ .04 Not signiﬁcant
Accelerated phase OR 2.4 (.5-12.2) P ¼ .29 n.p.
Acute GVHD grades II-IVy OR .6 (.1-2.8) P ¼ .54 n.p.
Extensive chronic GVHDy OR 2 (.4-10.3) P ¼ .40 n.p.
MUD indicates matched unrelated donor; PBSC, peripheral blood stem cell;
BMT, bone marrow transplantation; n.p., not performed (because P not
statistically signiﬁcant).
Univariate analysis was performed with the chi-square test, as described in
Methods, whereas multivariate analysis was performed by step-wise
logistic regression analysis, as described in Methods. Values are odds ratio
(OR), with 95% conﬁdence intervals in parentheses.
* P > .5 for both factors in multivariate analysis.
y Acute GVHD grades I-IV and all chronic GVHDwere also tested andwere
not associated with the detection of BCR-ABL.1384) after their ﬁrst positive result, resulting in an actuarial
probability of relapse of 15.8% as determined by Kaplan-
Meier analysis. Instead, none of the 11 patients with persis-
tent undetectable results relapsed during the follow-up
period (Figure 1). However, the difference between the two
groups was not signiﬁcant (P ¼ .19), as determined by
the log-rank test. The risk of relapse was not inﬂuenced by
the number of occurrences of a <MR3 result or by the time
since transplantation when a <MR3 result was ﬁrst detected
(Figure 2). We then tested whether detectable BCR-ABL
transcripts correlated with relapse in patients with acceler-
ated phase (n¼ 20) at the time of transplantation, a subset of
patients with a particularly high risk of relapse. However,
only 1 of 20 patients with accelerated phase relapsed during
follow-up, although 18 of them had detectable BCR-ABL
transcripts during follow-up (not shown). As MRD in CML
has been reported to be common early posttransplantation,
we performed a separate analysis on patients who were
monitored starting at the time of transplantation (n ¼ 15).
However, all 15 patients transplanted after 2002 had
detectable BCR-ABL transcripts, and 3 of them relapsed,
making it not possible to detect the impact of molecular
status on relapse.
To determine the outcome of patients with detectable
BCR-ABL transcripts who did not relapse, we reviewed their
molecular status at last follow-up. After a median of 1595
days (range, 22 to 2298) from the ﬁrst <MR3 result, only 11
of 46 patients (21%) still had detectable BCR-ABL transcripts
(not shown).
Figure 3 describes the results of molecular monitoring in
the 6 patients who relapsed. All these patients had detect-
able BCR-ABL transcripts before relapse. One-half of them
(UPN 273, 279, and 383) had their ﬁrst <MR3 result at 3 to 8
years posttransplantation, which was followed by relapse
within 1 to 3 years. The remaining 3 patients (UPN 536, 547,
and 553) were followed starting at the time of trans-
plantation and had ﬂuctuating BCR-ABL transcript amounts
(at least 2 separate <MR3 results) before relapse.
Finally, we determined the diagnostic accuracy of the
detection of BCR-ABL transcripts, by RT Q-PCR, in the
prediction of relapse. Although the detection of BCR-ABL
transcripts showed high sensitivity with no false-negative
results, resulting in a negative predictive value of 100%, its
speciﬁcity was low (19%), resulting in a poor positive
predictive value (Table 5).
DISCUSSION
In this study of long-term follow-up of patients with CML
after allogeneic HSCT, we observed that low levels of BCR-
ABL transcripts, consistent with <MR3 (BCR-ABL/ABL
ratio <.1% International Scale), were detected in most
patients after allogeneic HSCT. We observed that none of the
patients with stable undetectable BCR-ABL relapsed,
whereas patients with <MR3 results had a low relapse
probability of 15.8%. With the limits of the small number of
patients, the difference was not statistically signiﬁcant.
Therefore, the detection of BCR-ABL transcripts by RT Q-PCR
posttransplantation in CML patients may not effectively
predict clinical relapse with sufﬁcient speciﬁcity.
Competitive RT-PCR and RT-PCR with older techniques,
such as “LightCycler,” was estimated to have about 102
sensitivity and a good correlation with the results of FISH
(Fluorescent In Situ Hybridization) analysis [7], which has
often been reported to predict relapse of CML post-
transplantation. However, Kitzis et al. reported that BCR-ABL
Table 4
Characteristics of the 6 Relapsed Patients
UPN Age (yr) Status Interval Interferon Glivec Conditioning Regimen Acute GVHD ChronicGVHD Donor Source
273 37 Chronic phase 23 Y N CyþATGþTBI 0 L MUD BM
379 30 Chronic phase 11 Y N CyþATGþTBI 0 No MUD BM
383 40 Chronic phase 14 N N CyþBu 0 No Family BM
536 50 Accelerated phase 38 Y Y CyþBu 0 E Family PBSC
547 49 Chronic phase 13 N Y CyþBuþATG 0 L Family BM
553 28 Chronic phase 24 Y Y CyþATGþTBI 0 No MUD BM
Cy indicates cyclophosphamide; Bu, busulfan; TBI, total body irradiation; MUD, matched unrelated donor; BM, bone marrow; PBSC, peripheral blood stem cell;
L, limited; E, extensive.
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than RT Q-PCR analysis [22]. A review of the literature pub-
lished in 2000 suggested that repeated detectable BCR-ABL
mRNA levels, as determined by RT Q-PCR, could have been
predictive of relapse after allogeneic HSCT [6], although its
value was higher if associated with the presence of mixed
chimerism by VNTR (Variable Number of Tandem Repeats)-
PCR analysis, moreover if both mixed chimerism and MRD
were increasing [23]. We also previously observed that
persistent high amounts of BCR-ABL transcripts were asso-
ciated with relapse, particularly in patients with accelerated
phase disease [3]. Moreover, Kaeda et al. suggested that
ﬂuctuating BCR-ABL transcript levels correlatedwith a higher
probability of relapse in CML patients who underwent T
celledepleted allogeneic HSCT [9]. Several other studies
pointed out that high levels of BCR-ABL transcripts, particu-
larly if detected early (within 1 year) posttransplantation,
confer a signiﬁcantly higher risk of relapse [24-26]. It is
reasonable that such different results are mostly related to
different methods used to monitor MRD among populations
composed of patients with different characteristics and
treated with different types of GVHD prophylaxis (e.g., use of
ATG or of in vitro T cell depletion) or conditioning regimen
(e.g., total body irradiation). Moreover, our method of RT
Q-PCR has a sensitivity of up to 1 in 106 cells, possibly higher
than previously described.
However, the results of our study are also consistent with
other reports that did not conﬁrm the association between
detection of BCR-ABL and relapse. A meta-analysis on qual-
itative PCR published in 1994 conﬁrmed persistent PCR
positivity within 2 years as not predictive of relapse in CML
patients after allogeneic HSCT [27], later conﬁrmed byFigure 1. Kaplan-Meier analysis of the time from ﬁrst detection of BCR-ABL to
relapse of <MR3 patients (n ¼ 52) compared with patients with persistent
undetectable results (n ¼ 11). The signiﬁcance of the difference between the 2
groups of patients, as indicated in the plot, was determined by the log-rank
test.Santini et al. [28] using nested PCR. Furthermore, Otazú et al.
also showed 30 patients with detectable BCR-ABL transcripts
both early and late posttransplantation, reporting only 1
relapse among them [29].
The biological signiﬁcance of persistent detectable BCR-
ABL transcripts after allogeneic HSCT is still a matter of
debate. It could be explained by transient or intermittent
BCR-ABL positivity related to the detection of nonmalignant
BCR-ABLepositive leukocytes, as previously described for RT
PCR analysis as well [30,31]. Indeed, in our study, of 52
patients, only 11 patients had still detectable BCR-ABL tran-
scripts at last follow-up, after a median of 1595 days from the
ﬁrst event. Otherwise, the graft-versus-leukemia effect can
play a role in maintaining remission and in controlling
potential malignant recipient cells [32]. It would be inter-
esting, in future studies, to determine whether the frequency
of leukemia-speciﬁc Tcells [33]may correlatewith the risk of
clinical relapse in the patients with detectable BCR-ABL
transcripts.
The factors predicting persistent <MR3 posttrans-
plantation are still poorly characterized. First, the occurrence
of acute GVHD grades II to IV did not appear to correlate with
undetectable BCR-ABL transcripts, contrary to that previously
suggested [9] in patients receiving T celledepleted trans-
plantations; in our study, we could not ﬁnd any correlation
between chronic GVHD and molecular relapse, as previouslyFigure 2. Kaplan-Meier analysis of the time from ﬁrst detection of BCR-ABL to
relapse of patients in the <MR3 group as based on the indicated factors: (A)
number of events and (B) time to event. The signiﬁcance of the difference
between the 2 groups of patients, as indicated in the plot, was determined by
the log-rank test.
Figure 3. Results of molecular monitoring in the 6 relapsed patients. Red
circles represent <MR3 results, white circles represent undetectable values,
and red triangles represent relapse.
M. Arpinati et al. / Biol Blood Marrow Transplant 19 (2013) 735e740 739suggested [30]. Second, ATG appeared to be the only signiﬁ-
cant (P¼ .01) risk factor in univariate, but not in multivariate,
analysis. In our study, ATG was administered at a low dose to
60% of patients.We and others previously described that low-
dose ATG in the preparative regimen for both related [34] and
unrelated [35,36] bone marrow transplantation for CML was
not associated with a higher risk of relapse but only with
a lower incidence of acute and chronic GVHD [16]. Presently,
no reports speciﬁcally address the effect of ATG onMRD after
allogeneic HSCT for CML patients. Third, positive BCR-ABL
transcripts by RT Q-PCR analysis may be related to the
disease status at transplantation. Our study involved patients
both in chronic and accelerated phases (43 and 20, respec-
tively), but we could ﬁnd no evidence that the accelerated
phase was signiﬁcantly associated with persistent <MR3
results, possibly due to the low number of cases. Indeed,
detectable transcripts are reported early posttransplantation
irrespective of CML phase [28], although in 2000 Martinelli
et al., by using RT Q-PCR, showed a possible link between
BCR-ABL positivity and accelerated phase [3].
Maintenance of CR [complete remission] after 5 years,
appears to be associated with a 15% to 20% long-term risk of
relapse [2] and with mortality rates approaching those of the
general population, consistent with our results. In our study,
among 28 patients (54%) with low-level BCR-ABL positivity
at >5 years posttransplantation, only 3 relapsed after
a median follow-up of 2783 days (range, 1659 to 5289).
However, our study does not give any signiﬁcant information
on the risk of relapse of the general CML population, as most
patients who received transplantation during the observa-
tional time were not included because of early death or
relapse.
Therefore, our study does not suggest that a low amount
of detectable BCR-ABL transcript after allogeneic HSCT
should indicate a preemptive treatment. Based on our data,
>8 patients should be treated to prevent 1 relapse. Many
different therapies (donor lymphocytes infusion, TKIs,
immunosuppressant withdrawal) may be used to obtain
a complete remission or to maintain low-level BCR-ABL
transcript levels in patients at risk of relapse [37,38]. The
role of immunotherapy and imatinib (or other TKIs) inTable 5
Accuracy of a <MR3 Result in Predicting Relapse
Sensitivity 100%
Speciﬁcity 19%
Positive predictive value 12%
Negative predictive value 100%obtaining a molecular or cytogenetic response in relapsed
patients still needs to be better deﬁned [39-41]. Because
most of these treatments are costly or potentially toxic, we
deem that a larger prospective study is needed to evaluate
preemptive treatment in selected patients to avoid over-
treatment. Moreover, the best choice between different
possible treatments is still under investigation. At the
moment, the recommendation is to simply watch patients
with MRD positivity by increasing the frequency of molec-
ular monitoring.
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